摘要
以曲妥珠单抗为代表的新型抗肿瘤药物的问世改变了乳腺癌的治疗策略,以精准治疗为指导,化疗药物、靶向药物联合用药是目前乳腺癌的主要治疗方式。基础研究表明,人类表皮生长因子受体-2(human epidermal receptor-2,HER-2)是心脏和肿瘤共同的关键基因。尽管基础研究肯定了抗HER-2药物尤其联合用药对心脏有明显的损伤,但越来越多的随机对照试验表明抗HER-2药物对心功能的影响是有条件、可控、可管理的。因此,明确抗HER-2药物的心脏毒性特点,加强对伴有高危因素乳腺癌患者心功能的监测,制订规范的日常诊疗流程,是合理使用抗HER-2药物的关键,也是肿瘤心脏病学专家探索的课题。
The advent of new antitumor drugs represented by trastuzumab has changed the treatment strategy for breast cancer.Guided by precise treatment,the combination of chemotherapy and targeted drugs is currently the main method of breast cancer treatment.Fundamental research shows that human epidermal receptor-2(HER-2)is a key gene common to both the heart and tumors.Although researches,which has confirmed that anti-HER-2,especially in combination with drugs,has significant damage to the heart,more and more randomized controlled trial data indicate that anti-HER-2 treatment has a significant effect on the heart.The impact of functions is conditional,controllable and manageable.Therefore,clarifying the cardiotoxicity characteristics of anti-HER-2 drugs,strengthening the monitoring of cardiac function in breast cancer patients with high-risk factors,and formulating standardized daily diagnosis and treatment procedures are the key to the rational use of anti-HER-2 drugs and also focus on cardio-oncology.
作者
李佳
王阿曼
吕海辰
刘莹
崔晓楠
夏云龙
刘基巍
方凤奇
Li Jia;Wang Aman;Lyu Haichen;Liu Ying;Cui Xiaonan;Xia Yunlong;Liu Jiwei;Fang Fengqi(Department of Oncology,the First Affiliated Hospital of Dalian Medical University,Liaoning,Dalian 116021,China;Department of Cardiology,the First Affiliated Hospital of Dalian Medical University,Liaoning,Dalian 116021,China)
出处
《中国医学前沿杂志（电子版）》
2020年第3期19-26,共8页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
基金
大连市医学科学研究计划项目(1812012)
恒瑞肿瘤研究基金(Y-HR2018-046)。
